COVID-19 mRNA疫苗的真实世界安全性概况:基于VAERS数据库的分析
该研究收集2020年12月至2021年10月15日VAERS数据库中BNT162b2和mRNA-1273疫苗的不良事件报告,进行描述性分析和病例-非病例分析,使用报告比值比(ROR)及95%置信区间比较两种mRNA疫苗的报告率差异,发现BNT162b2相比mRNA-1273在心肌炎、贝尔麻痹和过敏性休克等特别关注事件上存在报告比值比失衡。
要点
- 截至截止日期,VAERS共收到758,040份报告,其中辉瑞-BioNTech(BNT162b2)疫苗439,401份,Moderna(mRNA-1273)疫苗318,639份。
- 两种mRNA疫苗最常见的不良事件为头痛、疲劳、发热、头晕、恶心、疼痛、寒战和肢体疼痛。
- BNT162b2相比mRNA-1273在心肌炎(ROR 2.00;95%CI 1.93-2.06)、贝尔麻痹(ROR 1.34;95%CI 1.29-1.39)和过敏性休克(ROR 3.23;95%CI 2.96-3.53)等特别关注事件上存在报告比值比失衡。
核心结论
- 尽管识别出一些罕见不良事件,但这项上市后监测调查进一步提供了mRNA疫苗良好安全性概况的证据。
研究设计与样本
- 研究收集2020年12月至2021年10月15日期间VAERS数据库中BNT162b2和mRNA-1273 COVID-19疫苗的安全性数据,对接种后发生不良事件的个体进行描述性分析,并采用病例-非病例分析,以报告比值比(ROR)及95%置信区间作为统计参数检测两种mRNA疫苗报告率的差异。
主要发现
- 截至截止日期,VAERS共收到758,040份报告,其中439,401份与辉瑞-BioNTech(BNT162b2)疫苗相关,318,639份与Moderna(mRNA-1273)疫苗相关。
- 两种mRNA疫苗免疫后最常见的不良事件为头痛、疲劳、发热、头晕、恶心、疼痛、寒战和肢体疼痛。
- BNT162b2相比mRNA-1273在心肌炎(ROR 2.00;95%CI 1.93-2.06)、贝尔麻痹(ROR 1.34;95%CI 1.29-1.39)和过敏性休克(ROR 3.23;95%CI 2.96-3.53)等特别关注事件上存在报告比值比失衡。
关键数值与推荐
- BNT162b2相比mRNA-1273的心肌炎ROR为2.00(95%CI 1.93-2.06)。
- BNT162b2相比mRNA-1273的贝尔麻痹ROR为1.34(95%CI 1.29-1.39)。
- BNT162b2相比mRNA-1273的过敏性休克ROR为3.23(95%CI 2.96-3.53)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily clinical practice and were not detected earlier during clinical trials. METHODS: Safety data concerning the BNT162b2 and the mRNA-1273 COVID-19 vaccines were collected from the Vaccine Adverse Event Reporting System (VAERS) for the period from December 2020 to October 15, 2021. In addition to a descriptive analysis of individuals who experienced an adverse event after vaccination, a case-non-case analysis was performed by using the Reporting Odds Ratio with 95 % confidence interval as statistical parameter for detecting differences in reporting rates between the two mRNA vaccines. RESULTS: At the cut-off date, a total of 758,040 reports were submitted to VAERS, of which 439,401 were related to the Pfizer-BioNTech (BNT162b2) vaccine and 318,639 to the Moderna vaccine (mRNA-1273). Most common adverse events following immunization for both mRNA vaccines were headache, fatigue, pyrexia, dizziness, nausea, pain, chills, and pain in extremity. A disproportionality was found for BNT162b2 as compared with mRNA-1273 for some events of special interest, such as myocarditis [ROR 2.00; 95 % confidence interval (CI), 1.93-2.06], Bell's palsy (1.34; 1.29-1.39), and anaphylactic shock (3.23; 2.96-3.53). CONCLUSION: Even if some rare adverse events were identified, our survey of post-marketing surveillance has provided further evidence of the favourable safety profile of mRNA vaccines.
引用
- Santi Laurini G, Montanaro N, Broccoli M, et al. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database. Vaccine. 2023. PMID: 37024412. doi:10.1016/j.vaccine.2023.03.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。